Background-To expand the paucity of data on the efficacy of various drug-eluting stents in diabetic patients. Methods and Results-Type 2 diabetic patients treated in our institution from October 2005 to January 2007 presenting with of de novo lesions in native coronary arteries were randomly assigned to sirolimus-eluting stents (Cypher group; nϭ76); paclitaxel-eluting stents (Taxus group; nϭ75); and everolimus-eluting stents (Endeavor group; nϭ75). Poor metabolic control (HbA1c Ͼ7% and low-density lipoprotein cholesterol Ͼ100 mg/dL) and microvascular complications (retinopathy and/or nephropathy) were assessed. The primary end point was the 3-year composite of major adverse cardiac events (MACE), including death of any cause, myocardial infarction, and clinically driven target vessel revascularization. MACE-free survival was 86.8% in the Cypher group, 82.5% in the Taxus group, and 64.4% in the Endeavor group (Pϭ0.006 by log-rank test). The post hoc comparisons showed no significant difference between Cypher versus Taxus groups (adjusted Pϭ1.0) but a higher MACE rate in the Endeavor group versus both the Cypher group (adjusted Pϭ0.012) and the Taxus group (adjusted Pϭ0.075). Independent predictors of 3-year MACE at Cox analysis were treatment by Endeavor versus Cypher stent (2.35 [95% confidence interval, 1.07 to 5.41]; Pϭ0.030), multivessel disease (hazard ratio, 1.78 [95% confidence interval, 1.06 to 2.66]; Pϭ0.031), diabetic retinopathy (hazard ratio, 1.60; [95% confidence interval, 1.03 to 2.76]; Pϭ0.038), and poor metabolic control (hazard ratio, 1.60; [95% confidence interval, 1.02 to 2.52]; Pϭ0.048). Conclusions-The present pilot study suggests that in diabetic patients, the Endeavor stent is associated with a higher 3-year MACE rate when compared with Cypher and Taxus stents. (Circ Cardiovasc Interv. 2011;4:121-129.)
myocardial revascularization were screened for enrollment ( Figure  1 ). Patients were classified as having diabetes mellitus according to the current guidelines. 13 One hundred ninety-six were excluded because of (1) previous myocardial revascularization (nϭ71), (2) indication for surgical revascularization (nϭ110), or (3) refusing to participate (nϭ15). Finally, 226 patients were randomly assigned into 1 of the following 3 treatment arms: Cypher group (nϭ76), Taxus group (nϭ75), and Endeavor group (nϭ75). Patients were randomly assigned according a computer-generated randomization list. The random assignment was done in all instances before starting the intervention, even in the case of chronic total occlusion. The local ethics committee approved the study protocol, and all patients gave written informed consent.
Microvascular Complications
All patients were screened for microvascular complications (nephropathy and retinopathy). 14 Diabetic retinopathy was graded as nonproliferative or proliferative. 15 Diabetic nephropathy was defined as a protein excretion rate Ն30 mg/24 h (ie, microalbuminuria). Proteinuria was determined by an immunometric assay (NycoCard U-Albumin, Axus-Schiled PoCAS, Oslo, Norway). 16 
Metabolic Control
Lipid control was considered optimal when the low-density lipoprotein cholesterol was Ͻ100 mg/dL. Glycosylated hemoglobin (HbA 1c ) was considered optimal when Ͻ7.0% (Biorad Diamat automated glycosylated hemoglobin analyzer). Optimal and poor metabolic control were defined as optimal and, respectively, suboptimal control of both glycemia and lipidemia. Acceptable metabolic control was defined as at least 1 parameter satisfied.
Myocardial Revascularization Interventions
A randomly assigned SES (Cypher Select, Cordis, Johnson & Johnson Co, Miami Lakes, FL), PES (Taxus Libertè, Boston Scientific Corporation, Natick, MA), or ZES (Endeavor Sprint, Medtronic CardioVascular, Santa Rosa, CA) was implanted in each patient, following current clinical practice. All patients received aspirin 325 mg and clopidogrel (75 mg daily) before stent deployment, with a loading dose (300 mg of clopidogrel) given to patients who were not pretreated. Patients received unfractionated heparin or bivalirudin. Glycoprotein IIb/IIIa inhibitors were administered according to the operator's judgment.
In patients with multivessel coronary artery disease and/or left main stenosis, the complexity of coronary artery disease was quantified using the SYNergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) score. 17 A staged procedure (defined as an additional percutaneous revascularization procedure performed within 30 days from discharge from the index hospitalization) was allowed in cases with chronic occlusion and complex multivessel disease. In such cases, the same DES used for the index procedure was used for the staged procedure.
Postprocedure Management and Follow-Up
Dual antiplatelet therapy (DAT), consisting in the administration of aspirin (325 mg/d) and clopidogrel (75 mg daily for 6 to 12 months), was prescribed to all patients. Clinical follow-up was performed by a visit at the outpatient clinic or by a telephone interview with the patient at 6, 12, 24, and 36 months. Inducible myocardial ischemia was assessed at least once a year in all patients by noninvasive tests (stress-echocardiography or scintigraphy), unless the clinical conditions made it unnecessary.
Study End Point
The primary end point for the study was the composite of major adverse cardiac events (MACE) at 3 years (intention-to-treat analysis). MACE encompassed death of any cause, nonfatal myocardial infarction, and clinically driven target lesion revascularization (TLR) or target vessel revascularization (TVR). Routine angiographic follow-up was discouraged; therefore all reinterventions were considered clinically driven. The secondary end point was the assessment of the role of microvascular complications and metabolic control in predicting long-term MACE.
Periprocedural myocardial infarction was defined as an increase in creatine kinase-MB elevation Ͼ3 times upper reference limit alone or associated with chest pain or ST-segment or T-wave abnormalities. 18 A new spontaneous myocardial infarction at follow-up was defined as the association of Ն1 clinical and Ն1 biological criteria: acute-onset chest pain and/or typical modification on ECG (STsegment or T-wave modification or new left bundle-branch block) and an increase in troponin Ͼ99th percentile of the upper reference limit. 18 TLR and TVR were characterized by ischemia-driven percutaneous or surgical revascularization of the treated lesion or vessel. Stent thrombosis was classified according to the definition proposed by the Academic Research Consortium. 18
Statistical Analysis
The TAXUS IV, SIRIUS, and other studies available at the time of the study design suggested yearly MACE rates of 9.2% and 15.6%. [1] [2] [3] [4] 19 Given that our study design encompassed a 3-year follow-up period and included second-generation DES with limited clinical data, we anticipated cumulative 3-year MACE rates of 40% for the worstperforming stent and of 15% for the best-performing stent. These figures, aiming for 80% power and 1.6% ␣ (ie, a 5% ␣ divided by 3, given the 3 planned pairwise comparisons), led to a sample size of 67 patients per group, which, taking into account potential losses during follow-up, were brought to at least 75 patients per group.
Continuous variables are presented as meanϮ1 SD or as median and Q1 to Q3 when appropriate. One-way ANOVA and Kruskal-Wallis tests were performed to determine differences between continuous variables when appropriate. Categorical variables were analyzed by 2 test. The Kaplan-Maier method was used to assess the primary end point. Comparisons between groups were performed by using the log-rank statistic. Secondary post hoc comparisons between groups were done with a Bonferroni adjustment. A covariate-adjusted Cox model was constructed to identify the independent predictor of the 3-year MACE and increase the study statistical power, given the multiple test issues. 20 Variables inserted into the covariate-adjusted Cox model were selected according to literature data and the study hypothesis. Tests were 2-sided. Probability values Ͻ0.05 were considered significant. Data were analyzed with SPSS for Windows, release 13.0 (SPSS Inc, Chicago, IL).
Results

Clinical Characteristics
Clinical and biochemical characteristics were comparable in the 3 groups (Table 1 and Table 2 ). There was a slightly lower rate of insulin treatment in the Taxus group (18%) compared with the Cypher (20%) and Endeavor (32%) groups (Pϭ0.11). The rate of diabetic retinopathy (Table 1 ) and nephropathy ( 
Angiographic Characteristics and Revascularization Strategies
Although not statistically significant, the rate of 3-vessel disease was slightly higher in the Cypher group (51.3%) compared with the Taxus (36%) and Endeavor (34%) groups (Pϭ0.12) ( Table 3 ). Less than 15% of patients had a high (ie, Ն33) SYNTAX score. More than half of the patients had left anterior descending artery stent implantation. Among the patients in the Cypher group, 1.09Ϯ0.37 vessels per patient were treated compared with 1.12Ϯ0.40 in the Taxus group and 1.06Ϯ0.22 in the Endeavor group (Pϭ0.49). The final stent length per patient was 26Ϯ16 mm in the Cypher group, 21Ϯ15 mm in the Taxus group, and 25Ϯ18 mm in the Endeavor group (Pϭ0.57).
In-Hospital and Long-Term MACE
The hospitalization period was uneventful in 85.5% of patients. Periprocedural myocardial infarction occurred in 10 (13.2%) patients of the Cypher group, in 10 (13.2%) patients of the Taxus group, and in 13 (17.3%) patients of the Endeavor group (Pϭ0.71). There were no deaths or repeat revascularizations ( (Table 4 ). Interestingly, the higher MACE rate in the Endeavor group was observed after the first year from intervention ( Figure 2) . Indeed, the majority of the repeat revascularizations occurred within 12 months in the Cypher (6/8 [75%]) and Taxus (7/11 [64%]) groups; in the Endeavor group, repeat revascularizations were roughly equally distributed between the first (9/21 [43%]) and the second (10/21 [48%]) year of follow-up. This difference in MACE rate was not affected by performing revascularization with staged procedure; Figure 3 ) and without diabetic retinopathy (Figure 4) 
Predictors of MACE
The following variables were included into the statistical model as potential factors affecting outcome: Endeavor group, diabetic retinopathy, diabetic nephropathy, chronic kidney disease, insulin treatment, poor metabolic control, female sex, age Ͼ65 years, left ventricular ejection fraction (Table 5 ).
Discussion
The main finding of the present pilot study focusing on DES implantation in diabetic patients is that the 3-year MACE rate is higher with the Endeavor Sprint ZES compared with the Cypher Select SES and the Taxus Libertè PES.
DES in Diabetic Patients
Compared with bare metal stents, TLR rates are strongly decreased by the use of SES or PES in patients with diabetes. [1] [2] [3] [4] 7, 10, 19, [21] [22] [23] [24] [25] Because the available data show no improvement in death or the incidence of myocardial infarction, the most interesting aspect relates to how helpful DES might be in reducing the rate of restenosis. However, there is a paucity of data on the efficacy of various DES in diabetic patients. It has been hypothesized that the mechanisms of action of drugs eluted by stents may be important in relation to the nature of underlying diseases, in that the effectiveness of sirolimus may be attenuated in people with diabetes mellitus. 26 Some prospective, randomized trials found that the use of SES is associated with a reduced risk of TLR compared with the use of PES, 5, 6 whereas other randomized trials and registries revealed no differences between these 2 DES. 5, 8, 9 Analysis of the diabetics subgroup in the ENDEAVOR IV trial suggests that ZES and PES have a virtually identical rates of TLR and TVR and safety end points at 1 year. 27 However, a longer follow-up is an important issue with the use of DES. On this point, our pilot study demonstrates that at 3-year follow-up, the Endeavor Sprint ZES has the worst performance-revealed as higher rates TLR and TVR-of the 3 DES used in our diabetic patients. Diabetes mellitus is associated with more aggressive neointimal hyperplasia response to stenting and thus with a higher risk of restenosis. ZES has a higher late loss as compared with SES and PES. 11, 12 This suggests that when dealing with patients with diabetes mellitus, it is important to select a DES with a strong antirestenotic effect. The RESOLUTE trial recently demonstrated that the new Endeavor Resolute ZES is not inferior to the everolimus-eluting stent. 28 Although the reported antirestenotic effect of the Endeavor Resolute ZES appears to be superior to the Endeavor Sprint ZES, 11, 28 we still must interpret the results with caution because of (1) the lack of subgroup analysis on diabetic patients (Ͻ25% of the global population) and (2) the relatively short-term follow-up (13 months). Concerns have been raised on the safety of these firstgeneration DES, especially in diabetic patients. 10, 29, 30 The restricted duration of DAT (Ͻ6 months) in early trials has been associated with the reported increased risk of death. 30 In our study, approximately 95% of patients received DAT for 6 months or more, and this may explain the low rates of death and myocardial infarction observed by us. Furthermore, in agreement with a recent meta-analysis focusing on the association between late loss and stent thrombosis, our results do not support the hypothesis that late loss could be a proxy for healing processes, and thus that very low (and especially negative) late loss values could lead to late stent thrombosis. 31
Multivessel Disease, Diabetic Retinopathy, and Metabolic Control
Diabetic patients with a more complex and severe coronary artery disease had a more unfavorable outcome after percutaneous myocardial revascularization. The anatomic patterns of coronary artery disease in diabetic patients may influence their prognosis and response to revascularization. This concept has been recently highlighted through the use of the SYNTAX score as a measure of complexity. 17 Diabetic retinopathy represents an independent predictor of 3-year MACE after DES implantation in diabetic patients. 32, 33 The relative small number of patients may explain why we did not observed a worse outcome in patients requiring insulin therapy. However, the assessment of microvascular complications (retinopathy and nephropathy) is a more sensitive marker of the severity of diabetes, irrespective of the therapy.
In the BARI 2D, an HbA 1 c Ͻ7% was observed in 39.6% of patients at baseline and 48% at 3-year follow-up, and the low-density lipoprotein cholesterol was found to be Ͻ100 mg/dL in 59.5% at baseline and 83% at 3-year follow-up. 34 Although previous studies suggest a better outcome in patients with good metabolic control, 14 it is still controversial whether intensive therapy has a benefit in patients with long-standing type 2 diabetes. 35 
Study Limitations
This is an open-label study. In addition, the small number of enrolled patients limits the power to detect meaningful differences in safety end points. Indeed, we acknowledge that the observed stent thrombosis rate in the present trial may be due to (1) the small sample size and (2) the difference in the proportion of insulin treatment in the 3 groups. Therefore, we For continuous variables, the median value was used as a cutoff point to define the 2 subgroups with the characteristic (that is, major adverse cardiac events) present or absent. 
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cannot draw any conclusion on this aspect. Finally, the results of the present study refer only to patients with type 2 diabetes mellitus.
Clinical Implications
The performance of the Endeavor Sprint ZES in diabetic patients appears to be worse than that of SES and PES, being associated with a higher 3-year MACE rate. The results of the present pilot study must be confirmed in further larger studies.
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